Shares of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) today surged 54.8% after the company released positive results for the Phase 1 study of its CPI-006 COVID-19 drug, which is based on a novel immunotherapy approach.
Today’s data was based on a 56-day follow up study on three cohorts of patients who had been treated with the drug and showed a dose-response, with higher and more prolonged titers of anti-SARS-CoV-2 antibodies in the 1.0 mg/kg cohort compared to the 0.3 mg/kg cohort.
There were also no drug-related safety issues in any of the 15 patients treated as of September 17, 2020, with all patients showing increased levels of memory B cells and memory T cells.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
As a clinical-stage biopharmaceutical company, Corvus expects to complete the Phase 1 study by the end of Q4 2020.
Richard A. Miller, M.D., the President and CEO of Corvus said: “We continue to see consistent, promising results with CPI-006 in hospitalized COVID-19 patients,”
Adding: “The data supports continued evaluation of CPI-006 in this patient population, and potentially in outpatients with COVID-19 and in other infectious diseases. We are also exploring the potential use in combination with preventative vaccines under development by third parties to enhance and prolong immunity.”
Corvus Pharma Inc share price
Corvus Pharma share price today surged 54.8% to trade at $6.30 having ended Friday’s session trading at $4.07.
People who read this also read:
